

Rev03  
 Update: Aug,08,2025
**DATASHEET**


# HLA-A\*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer, His & Avi, Human

Cat. No.: Z06583


## Product Introduction

<b>Species</b>	Human
<b>Protein Construction</b>	<div style="display: flex; align-items: center; justify-content: space-between;"> <div style="background-color: #0056b3; color: white; padding: 5px; text-align: center;">             HLA-A*02:01&amp;B2M&amp;NY-ESO-1 (SLLMWITQV) Tetramer[Gly25-Thr305(HLA-A*02:01), Ile21-Met119(B2M) and SLLMWITQV peptide]              Accession # A0A140T913(HLA-A*02:01)&amp;P61769(B2M)&amp;SLLMWITQV           </div> <div style="background-color: #90c090; padding: 5px; text-align: center;">His</div> <div style="background-color: #4f81bd; padding: 5px; text-align: center;">Avi</div> </div> <p style="text-align: center; margin-top: 5px;">N-term <span style="float: right;">C-term</span></p>
<b>Purity</b>	> 95% as determined by BisTris PAGE > 95% as determined by HPLC
<b>Endotoxin Level</b>	Less than 1EU per µg by the LAL method.
<b>Biological Activity</b>	Measured by its binding ability in a functional ELISA. Immobilized HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer, His & Avi, Human at 5µg/ml (100µl/well) on the plate can bind Anti-HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Antibody, hFc Tag. Test result was comparable to standard batch.
<b>Expression System</b>	HEK293
<b>Theoretical Molecular Weight</b>	258 kDa
<b>Apparent Molecular Weight</b>	Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
<b>Formulation</b>	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4).
<b>Reconstitution</b>	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
<b>Storage &amp; Stability</b>	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

## Examples




HLA-A\*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.



Log Anti-HLA-A\*02:01&B2M&NY-ESO-1 Antibody, hFc Tag Conc. (ng/ml)

Immobilized HLA-A\*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer, His & Avi, Human, His Tag at 5 µg/ml (100 µl/well) on the plate. Dose response curve for Anti-HLA-A\*02:01&B2M&NY-ESO-1 Antibody, hFc Tag with the EC50 of 1.0 ng/ml determined by ELISA.



The purity of HLA-A\*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

## Background

**Target Background :** NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.

**Synonyms :** MHC; MY-ESO-1; CT6.1; LAGE-2; CTAG1; CTAG1B; ESO1CTAG; LAGE2A; NY-ESO-1; CTAG1A

**For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.**

Confidential and Privileged



Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28Yongxi Road, Jiangning District, Nanjing, Jiangsu, China

---

**GenScript USA, Inc.**

860 Centennial Ave. Piscataway, NJ 08854

Tel: 1-732-885-9188